Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
EMCURE.NS
Strong BuyPremium GrowerEmcure Pharmaceuticals Limited · Healthcare · India · $3.9B · Avg Vol: $3M/d
81
StockRankGet insider-trade alerts
Q
71
V
27
M
79
P/E (TTM)
35.9x
ROE
18.7%
D/E
0.3x
Dividend %
0.2%
COMPANY DESCRIPTION
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynaecology, cardiovascular, blood-related, pain and analgesics, oncology/anti-neoplastics, anti-infectives, vitamins, minerals and nutrients,...
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 59.3B | 65.8B | 78.1B | 91.2B | 15.4% | 96.8B | 104.9B | 118.6B | 14.0% |
| EPS (INR) | 29.43 | 27.57 | 36.43 | 48.77 | 18.3% | 53.34 | 58.82 | 72.71 | 22.1% |
| Shares | 189.1M | 189.1M | 189.5M | 189.6M | +0.3% | 189.7M | — | — | — |
| Debt | 23.3B | 23.3B | 10.2B | 15.2B | -13.3% | 15.2B | — | — | — |
| Equity | 25.0B | 29.5B | 44.5B | 49.5B | 25.6% | — | — | — | — |
| Op CF | 7.5B | 11.0B | 8.5B | 9.4B | 8.1% | 9.4B | — | — | — |
| Inv CF | -4.7B | -7.1B | -940.0M | -11.9B | — | — | — | — | — |
| Fin CF | -1.5B | -1.6B | -8.1B | 3.4B | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+0.4%
SMA 50SMA 200
Close
$20.13
RSI (14)
59.0
52W High
$21.49
From 52W High
0.9%
SCORE BREAKDOWN
Quality
71
ROIC
27.0%95.3
ROE
18.7%87.2
GP/Assets
59.9%90.9
Op. Margin
15.4%75.8
FCF/Assets
4.1%66.0
Piotroski
549.3
Int. Cover
10.4x62.4
D/E Ratio
0.31x40.6
Current Ratio
1.43x24.6
Value
27
P/E (TTM)
35.9x33.1
EV/EBITDA
19.9x34.6
P/FCF
92.6x16.8
P/B
7.3x17.6
P/S
3.8x50.6
Div Yield
0.2%4.0
Momentum
79
52W High %
94%91.2
RS 6M
27%84.0
SMA 50/200
1.15x82.6
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+45%52.0
Q Growth
42%70.9
FUNDAMENTALS
Market Cap
$3.9B
P/E (Forward)
24.7x
Gross Margin
59.4%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of EMCURE.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| EMCURE.NS | Emcure Pharmaceuticals Limited(you) | $3.9B | 81 | Strong Buy |
| AJANTPHARM.NS | Ajanta Pharma Limited | $4.7B | 79 | Buy |
| ABBOTINDIA.NS | Abbott India Limited | $5.7B | 78 | Buy |
| GLAND.NS | Gland Pharma Limited | $5.1B | 88 | Strong Buy |
| GRANULES.NS | Granules India Limited | $2.3B | 87 | Strong Buy |
| CAPLIPOINT.NS | Caplin Point Laboratories Limited | $2.2B | 86 | Strong Buy |
| IPCALAB.NS | Ipca Laboratories Limited | $5.3B | 91 | Strong Buy |
| APLLTD.NS | Alembic Pharmaceuticals Limited | $1.7B | 84 | Strong Buy |
| NEULANDLAB.NS | Neuland Laboratories Limited | $3.2B | 64 | Hold |
| ALKEM.NS | Alkem Laboratories Limited | $6.5B | 69 | Buy |
Peer medians: ROE 11.8% · P/E 42.8x · Gross margin 59.4%